CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$45.37 USD
+0.47 (1.05%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $45.28 -0.09 (-0.20%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$45.37 USD
+0.47 (1.05%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $45.28 -0.09 (-0.20%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Zacks News
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today
by Zacks Equity Research
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $45.71, indicating a +0.29% shift from the previous trading day.
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $45.92, marking a -1.86% move from the previous day.
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $49.49, denoting a -0.2% change from the preceding trading day.
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $49.59, marking a -0.56% move from the previous day.
Vertex Stock Loses Around $3B in 3 Months: Buy the Dip or Steer Clear?
by Kinjel Shah
VRTX is a good stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress.
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why
by Zacks Equity Research
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $45.51, representing a +1.42% change from its previous close.
Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?
by Sundeep Ganoria
Despite gaining regulatory approvals in many countries for the first ever CRISPR-based gene therapy, investors should remain wary of investing in CRISPR Therapeutics' (CRSP) early-stage pipeline.
Vertex (VRTX) Stock Outperforms Industry YTD: Here's Why
by Zacks Equity Research
Vertex's (VRTX) CF sales are expected to remain strong despite a slight slowdown in the growth rate. Casgevy and suzetrigine (if approved) are set to provide the necessary diversification from the CF franchise.
The Zacks Analyst Blog Vertex Pharmaceuticals CRISPR and Moderna
by Zacks Equity Research
Vertex Pharmaceuticals CRISPR and Moderna are included in this Analyst Blog.
Here's How to Play Vertex (VRTX) Stock After Q2 Loss, Price Dip
by Kinjel Shah
Vertex (VRTX) is a great stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress.
CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected
by Zacks Equity Research
CRISPR Therapeutics (CRSP) incurs a wider-than-expected loss in the second quarter of 2024. The commercial launch of CRISPR-based gene therapy, Casgevy, is progressing well.
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -8.76% and 93.84%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Vertex (VRTX) Q2 Loss Wider Than Expected, '24 Sales View Raised
by Zacks Equity Research
Vertex (VRTX) incurs a wider-than-expected loss in the second quarter while sales come in line with estimates. Vertex raises its full-year product revenue guidance.
Gilead Sciences (GILD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings?
by Ekta Bagri
While Prime Medicine's (PRME) pipeline progress is encouraging, the precarious cash position is worrisome. We advise a wait-and-watch approach before Q2 results.
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
by Zacks Equity Research
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of 92.54% and 810.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Vertex (VRTX) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Ahan Chakraborty
Vertex's (VRTX) second-quarter revenues are expected to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
CRISPR Therapeutics (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Best ETFs of Last Week
by Sanghamitra Saha
Wall Street offered a mixed performance last week.
CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $57.92, signifying a +0.61% move from its prior day's close.
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $57.19 in the latest trading session, marking a +1.69% move from the prior day.
Is a Beat in the Cards for CRISPR (CRSP) in Q2 Earnings?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) second-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its newly approved gene therapy, Casgevy, and other pipeline updates.
What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?
by Zacks Equity Research
On ADMA Biologics' (ADMA) second-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.